Mucoangin Mint (Ambroxol Hydrochloride)

Ambroxol Hydrochloride acts on mucus production and clearance in the respiratory tract, making it useful for several pulmonary conditions.

• Acute or chronic bronchitis: reduces mucus viscosity and stimulates surfactant secretion, promoting expectoration and helping relieve a productive cough in affected patients.
• Upper respiratory tract infections: thins thick secretions, enhances mucociliary clearance and improves breathing comfort during viral or bacterial infections of the nose, throat and sinuses.
• COPD exacerbations: enhances mucociliary transport, reduces airway obstruction and aids symptom control during acute flare‑ups in chronic obstructive pulmonary disease.

• Ambroxol Hydrochloride increases serous secretion from bronchial glands, stimulates surfactant production and activates ciliary activity. By reducing mucus viscosity and enhancing mucociliary clearance, it facilitates the removal of secretions from the airways. The compound also exerts local anti‑inflammatory effects on the respiratory epithelium, contributing to improved airway patency. These actions collectively improve airflow, reduce cough frequency, and support overall respiratory function during infection or exacerbation.

Ambroxol Hydrochloride may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Taste alteration or mild oral irritation
• Nausea or mild gastrointestinal discomfort
• Headache
• Dizziness

Serious or Rare Side Effects

• Allergic skin reactions such as rash or urticaria
• Severe bronchospasm or respiratory distress
• Anaphylactic shock (rare)

When using Mucoangin Mint, consider the following precautions to ensure safe and effective therapy.

• Contraindication: avoid use in patients with known hypersensitivity to ambroxol or excipients.
• Pregnancy: use only if clearly needed after evaluating risk–benefit; limited data available.
• Breastfeeding: caution advised; monitor infant for possible effects.
• Renal impairment: dose adjustment may be required in severe renal dysfunction.
• Drug interactions: review concomitant medications for potential interactions.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Ambroxol may interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Anticholinergic agents: may reduce mucolytic efficacy.
• Strong CYP3A4 inhibitors: could increase ambroxol plasma levels, raising risk of side effects.

Moderate Interactions (Monitor Closely)

• Bronchodilators (β2‑agonists): additive effects on airway smooth muscle may occur.
• Antibiotics such as macrolides: potential for enhanced gastrointestinal irritation.
• NSAIDs: may increase risk of gastrointestinal discomfort.